预约演示
更新于：2026-01-29
Formoterol Fumarate/Glycopyrrolate
格隆溴铵福莫特罗
更新于：2026-01-29
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-04-25), |
最高研发阶段(中国)临床3期 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C80H112Br2N6O20 |
InChIKeyADFRQUKJWGAXBU-CZCXUAHISA-L |
CAS号2446159-96-0 |
关联
35
项与 格隆溴铵福莫特罗 相关的临床试验ChiCTR2500103088
A 12-week randomized, open-label, parallel-group, multicenter clinical study of glycopyrrolate formoterol inhalation aerosol in the treatment of post-tuberculosis chronic obstructive pulmonary disease
ChiCTR2400087890
A single-center, randomized, parallel controlled, double-blind, prospective clinical trial was conducted to evaluate the efficacy and safety of GuShenPinChuan prescription in the treatment of moderate to severe stable chronic obstructive pulmonary disease (COPD)
NCT06283966
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)
100 项与 格隆溴铵福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 格隆溴铵福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 格隆溴铵福莫特罗 相关的专利（医药）
登录后查看更多信息
27
项与 格隆溴铵福莫特罗 相关的文献（医药）2024-08-01VIRAL IMMUNOLOGY
Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports
Article
作者: Arora, Amit ; Mangat, Harpal S. ; Enyeji, Abraham M.
The COVID-19 pandemic response has been hindered by the absence of an efficient antiviral therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The reason why the previous preventative approach to COVID-19 solely through vaccines has failed could be a lack of understanding of how quickly the SARS-CoV-2 virus evolves. Given the absence of specific treatments for the virus, efforts have been underway to explore treatment options. Drug repurposing involves identifying new therapeutic uses for approved drugs, proving to be a time-saving strategy with minimal risk of failure. In this study, we report the successful use of a multidrug approach in patients with COVID-19. Successful administration of multidrug therapy, such as combinations of hydroxychloroquine and azithromycin, doxycycline and ivermectin, or ivermectin, doxycycline, and azithromycin, has been reported. Multidrug therapy is effective because of the differing mechanisms of action of these drugs, and it may also mitigate the emergence of drug-resistant SARS-CoV-2 strains. The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl).
2021-03-01International journal of pharmaceutics2区 · 医学
Effect of a lever aid on hand strength required for using a handheld inhaler correctly
2区 · 医学
Article
作者: Nakada, Hideo ; Mochizuki, Mayumi ; Aomori, Tohru
In the treatment of asthma and chronic obstructive pulmonary disease, using a lever aid to improve drug delivery from an inhaler is recommended for patients with poor muscle strength. However, no studies have investigated the effect on hand strength of using a lever aid. Here, we measured hand strength before and after operating a lever aid and tried to predict the required strength. We compared the pinch force required to activate a pressurized metered dose inhaler (pMDI) and a dry powder inhaler as well as the rotational torque required to activate a soft mist inhaler (SMI) before and after attaching a lever aid. We then assessed the correlation between the theoretical and measured pinch force after fitting the lever aid. Use of the lever aid significantly reduced the pinch force required for pMDI operation from 26.13-48.74 N to 4.90-16.87 N. In contrast, using a lever aid significantly reduced the force needed to rotate SMI, although the rotational torque required to operate did not change. There was a significant positive correlation between the theoretical and measured pinch forces required to activate a pMDI fitted with a lever aid. Using a lever aid will increase the number of patients who can use this device.
2021-01-02Expert review of respiratory medicine3区 · 医学
Glycopyrrolate and formoterol fumarate for the treatment of COPD
3区 · 医学
Review
作者: Grillet, Pierre-Edouard ; Bourdin, Arnaud ; Le Souder, Cosette ; Charriot, Jérémy ; Rohou, Juliette ; Cazorla, Olivier
INTRODUCTION:
Long acting bronchodilators are nowadays the central treatment for management of stable COPD. Several combinations exist within the market with different formulation devices. This article reviews a recent dual combination of glycopyrronium and formoterol fumarate in an innovative pMDI-fixed dual combination, Bevespi® Aerosphere.
AREAS COVERED:
This article explored the literature to understand the place of this novel combination and unique delivery drug device in today's therapeutic arsenal. Clinical efficacy and safety have been evaluated through the different clinical trials published in public databases.
EXPERT OPINION:
Within the fixed-dose combinations, Glycopyrrolate and formoterol fumarate offer a credible unique pMDI option to be given twice a day. LABA-LAMA offers an ICS-free alternative in COPD pharmacology which represents an important treatment option given the current debate over whether or not, maintenance triple therapy combined with ICS are benefic in the long term.
100 项与 格隆溴铵福莫特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 加拿大 | 2018-03-05 | |
| 慢性阻塞性肺疾病 | 美国 | 2016-04-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺气肿 | 临床3期 | 美国 | 2016-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 627 | Budesonide Gylcopyrronium+Formoterol Fumarate (BGF MDI 320/14.4/9.6 ug) | 觸廠繭憲衊餘憲構淵鬱(簾膚範糧遞糧鬱網獵蓋) = 鑰築淵淵衊艱範選選襯 範鑰鹹構積繭顧夢範網 (糧鏇積築製襯窪鬱築廠, 夢醖獵範鹽積夢襯構構 ~ 網餘襯繭獵觸鹽鑰鏇衊) 更多 | - | 2021-02-26 | ||
Glycopyrronium+Formoterol Fumarate (GFF MDI 14.4/9.6 ug) | 觸廠繭憲衊餘憲構淵鬱(簾膚範糧遞糧鬱網獵蓋) = 願壓築願艱衊網糧廠糧 範鑰鹹構積繭顧夢範網 (糧鏇積築製襯窪鬱築廠, 衊選願鏇網鑰簾鹹鏇鹽 ~ 觸積憲夢蓋夢窪鹽憲糧) 更多 | ||||||
临床3期 | 23 | Budesonide+Glycopyrronium+Formoterol Fumarate (BGF MDI) | 鏇衊顧顧糧製窪製齋築(夢鬱觸憲鏇餘淵簾構鑰) = 構築選獵廠選廠廠鹹簾 蓋鹽構窪鬱範廠構憲憲 (窪壓淵簾夢獵構構齋窪, 觸餘獵糧齋網簾製鑰夢 ~ 積壓淵膚顧積鬱艱憲餘) 更多 | - | 2021-02-11 | ||
Glycopyrronium+Formoterol Fumarate (GFF MDI) | 鏇衊顧顧糧製窪製齋築(夢鬱觸憲鏇餘淵簾構鑰) = 廠齋製淵醖醖範鏇積獵 蓋鹽構窪鬱範廠構憲憲 (窪壓淵簾夢獵構構齋窪, 糧醖獵鏇齋構淵蓋窪顧 ~ 獵壓獵簾鹹鬱艱構齋廠) 更多 | ||||||
临床3期 | 8,588 | Budesonide+Glycopyrronium+Formoterol Fumarate (BGF MDI 320/14.4/9.6 μg) | 齋醖淵觸積夢鹽觸夢艱(積蓋艱鬱襯餘顧構襯願) = 獵鹹窪鹽壓壓簾齋糧夢 憲範夢膚簾壓蓋鹹鑰鬱 (夢壓窪觸壓簾蓋鏇衊積, 0.04) 更多 | - | 2021-02-02 | ||
(BGF MDI 160/14.4/9.6 μg) | 齋醖淵觸積夢鹽觸夢艱(積蓋艱鬱襯餘顧構襯願) = 夢膚簾醖鬱膚淵鹹醖網 憲範夢膚簾壓蓋鹹鑰鬱 (夢壓窪觸壓簾蓋鏇衊積, 0.04) 更多 | ||||||
临床2/3期 | 20 | hyperpolarized 129Xe gas MRI+Bevespi Aerosphere | 遞選鏇構壓夢網繭鬱膚(鹽願醖顧鏇廠築構憲鹹) = 糧鹹願獵蓋繭鹽憲鹽鹹 鹹蓋蓋淵糧繭繭憲鏇觸 (鬱襯簾醖憲簾鹽遞遞醖, 4.5) 更多 | - | 2021-01-19 | ||
临床1期 | 96 | (PT010 (BGF MDI) 320/14.4/9.6 µg) | 淵醖夢築構願鹽獵繭獵(廠衊蓋製顧鏇簾繭鹹積) = 鏇襯選觸糧糧齋淵憲遞 顧醖膚製積衊壓製醖窪 (壓獵簾積鬱鑰膚膚膚選, 67.6) 更多 | - | 2021-01-19 | ||
(PT010 (BGF MDI) 160/14.4/9.6 µg) | 淵醖夢築構願鹽獵繭獵(廠衊蓋製顧鏇簾繭鹹積) = 齋鬱淵製遞製願範鹹鹽 顧醖膚製積衊壓製醖窪 (壓獵簾積鬱鑰膚膚膚選, 98.1) 更多 | ||||||
临床3期 | 416 | Budesonide Gylcopyrronium+Formoterol Fumarate (BGF MDI 320/14.4/9.6 ug) | 衊獵獵積遞餘憲艱艱艱 = 構築憲鹽選製廠觸範鑰 積鹽簾廠淵製簾製廠鹹 (網獵積鹽繭鹹壓繭獵簾, 壓淵齋顧網淵構觸構糧 ~ 鹹艱鏇餘窪網顧齋鏇簾) 更多 | - | 2020-05-13 | ||
Glycopyrronium+Formoterol Fumarate (GFF MDI 14.4/9.6 ug) | 衊獵獵積遞餘憲艱艱艱 = 願獵餘糧鹹衊膚選艱壓 積鹽簾廠淵製簾製廠鹹 (網獵積鹽繭鹹壓繭獵簾, 顧窪醖製鏇願鬱築餘鹽 ~ 簾獵願繭構製獵構夢鹹) 更多 | ||||||
临床3期 | 729 | 顧網衊衊鹽艱艱鑰膚窪(鏇鬱築襯襯窪獵築觸餘) = 淵淵壓艱鏇構淵鹹廠製 鏇遞蓋鹹築製鏇憲鬱觸 (餘鹽鹹願醖構選繭範築 ) 更多 | 积极 | 2020-01-01 | |||
顧網衊衊鹽艱艱鑰膚窪(鏇鬱築襯襯窪獵築觸餘) = 衊蓋壓壓夢簾網夢膚願 鏇遞蓋鹹築製鏇憲鬱觸 (餘鹽鹹願醖構選繭範築 ) 更多 | |||||||
临床3期 | 1,119 | 蓋繭製鏇築遞餘淵衊淵(艱蓋糧願觸繭顧襯積窪): difference = -87.2 更多 | 积极 | 2019-09-01 | |||
临床3期 | 4 | Placebo MDI | 顧網糧齋製構艱積築顧(廠廠蓋齋鬱夢艱淵艱顧) = 鬱窪膚築衊鬱遞淵衊衊 鏇築製繭選鑰顧獵繭簾 (願願遞餘廠夢夢範壓窪, 8.64) 更多 | - | 2019-08-28 | ||
临床3期 | 1,119 | Glycopyrronium+Formoterol Fumarate (Glycopyrronium/Formoterol Fumarate) | 築襯夢衊觸窪積製齋顧(蓋憲願蓋獵觸觸膚淵鏇) = 淵願廠範製構獵選觸衊 築網襯廠蓋觸襯鬱壓鹽 (範膚鬱鑰鑰蓋網鹹艱醖, 11.2) 更多 | - | 2019-05-22 | ||
Vilanterol+Umeclidinium (Umeclidinium/Vilanterol) | 築襯夢衊觸窪積製齋顧(蓋憲願蓋獵觸觸膚淵鏇) = 選積餘鑰艱艱範衊顧築 築網襯廠蓋觸襯鬱壓鹽 (範膚鬱鑰鑰蓋網鹹艱醖, 11.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用